Association of serum coiled-coil domain containing protein 11 levels with coronary artery disease
By
Jie Gao
Hongping Wang
Wenjun Wang
WenYing Hu
PengYong Yan
Jun Lu
ZongJun Liu
June 15, 2026
Clinical Scorecard: Link Between Serum Levels of Coiled-Coil Domain Containing Protein 11 and Coronary Artery Disease
At a Glance
Category Detail
Condition Coronary Artery Disease (CAD) Key Mechanisms Atherosclerosis, inflammation, endothelial dysfunction Target Population Patients diagnosed with CAD Care Setting Inpatients undergoing coronary angiography
Key Highlights
Elevated serum CCDC11 levels in CAD patients compared to controls (20.4 vs. 13.8 ng/mL, P < 0.001) Positive correlation between CCDC11 levels and the number of affected coronary vessels (P for trend < 0.001) CCDC11 independently correlated with CAD in logistic regression analysis ROC analysis showed AUC for CCDC11 in CAD discrimination was 0.71, higher than CRP (0.56, P < 0.01) Optimal CCDC11 cutoff value identified at 19.37 ng/mL with sensitivity of 53.4% and specificity of 91.6% Guideline-Based Recommendations
Diagnosis
CAD diagnosed by angiographic findings with stenosis >50% in major coronary arteries Management
Monitoring & Follow-up
Risks
Exclusion criteria include acute myocardial infarction, valvular heart disease, severe hepatic or renal dysfunction, infections, and malignancies Patient & Prescribing Data
266 patients with CAD and 95 controls
CCDC11 may serve as a biomarker for CAD severity and presence
Clinical Best Practices
Utilize serum CCDC11 levels as a potential biomarker for CAD assessment Consider stratification of CAD patients based on the number of affected vessels Related Resources & Content
